Showing 111-120 of 1791 results for "".
- Turf Wars: Reports From the Front Linehttps://practicalneurology.com/columns/practice-management/turf-wars-reports-from-the-front-line/31111/In the October 2007 issue of Practical Neurology, Associate Editor Zac Haughn explores the complex landscape of professional conflicts and collaborations within the field of neurology. The article delves into the "turf wars" that arise when neurologists compete with other specialists, such as pulmon
Movement Disorders Moment: Environmental and Biologic Risk and Protective Factors Associated with Parkinson Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/movement-disorders-momentbrenvironmental-and-biologic-risk-and-protective-factors-associated-with-parkinson-disease/32120/This review provides a concise summary of the evidence for environmental and biologic risk and protective factors for Parkinson disease.Inclusive Research for Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/inclusive-research-for-multiple-sclerosis/31755/Inclusive research improves quality of scientific data, facilitates discovery of safety and efficacy, and assists in identifying population-specific differences.Drugs in Development for Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/drugs-in-development-for-multiple-sclerosis/31632/Stem cells, tyrosine kinase inhibitors, remyelinating agents, metabolically active molecules, and more are being tested as potential new disease-modifying treatments.Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/bruton-tyrosine-kinase-inhibition-in-multiple-sclerosis/31872/The missing link for treatment optimization?Neuro-Oncology Outlook: Advancements in Targeted Molecular Therapy for Low-Grade Gliomas—Challenging the Treatment Paradigm
https://practicalneurology.com/diseases-diagnoses/imaging-testing/neuro-oncology-outlookbradvancements-in-targeted-molecular-therapy-for-low-grade-gliomas-challenging-the-treatment-paradigm/32121/Treatment with the IDH inhibitor vorasidenib increased median progression-free survival and time to next intervention in individuals with grade 2 gliomas under surveillance after surgical resection.Beyond the Symptoms: The True Impact of gMG on Patients' Lives
https://practicalneurology.com/programs/cme/beyond-the-symptoms-the-true-impact-of-gmg-on-patients-lives/32235/While traditional gMG treatments bring many debilitating side effects, a more targeted approach focusing on the FcRn complex has shown great promise.FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy
https://practicalneurology.com/programs/cme/fcrn-antagonists-in-myasthenia-gravis-a-new-era-in-targeted-therapy/32242/While traditional gMG treatments bring many debilitating side effects, a more targeted approach focusing on the FcRn complex has shown great promise.Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies
https://practicalneurology.com/programs/cme/precision-medicine-in-myasthenia-gravis-crafting-personalized-treatment-strategies/32244/While traditional gMG treatments bring many debilitating side effects, a more targeted approach focusing on the FcRn complex has shown great promise.Diagnosing gMG: Navigating Current Tools and Approaches
https://practicalneurology.com/programs/cme/diagnosing-gmg-navigating-current-tools-and-approaches/32238/While traditional gMG treatments bring many debilitating side effects, a more targeted approach focusing on the FcRn complex has shown great promise.